Passage Bio

  • TickerPASG
  • ISINUS7027121000
  • ExchangeNASDAQ Stock Market
  • SectorPharmaceuticals & Biotechnology
  • CountryUnited States
 PRESS RELEASE
PASG PASSAGE BIO (Health Care)

Passage Bio Announces Inducement Award for Newly Appointed Chief Comme...

Passage Bio Announces Inducement Award for Newly Appointed Chief Commercial Officer Under Nasdaq Listing Rule 5635(c)(4) PHILADELPHIA, July 21, 2021 (GLOBE NEWSWIRE) -- Passage Bio, Inc. (Nasdaq: PASG), a clinical-stage genetic medicines company focused on developing transformative therapies for rare, monogenic central nervous system (CNS) disorders, today announced it has granted an inducement award to the company’s newly appointed Chief Commercial Officer, M. Maria Törnsén, under an inducement plan adopted by its board of directors. Passage Bio granted an option to purchase 200,000 s...

 PRESS RELEASE
PASG PASSAGE BIO (Health Care)

Passage Bio to Participate in Upcoming June Investor Conferences

Passage Bio to Participate in Upcoming June Investor Conferences PHILADELPHIA, May 26, 2021 (GLOBE NEWSWIRE) -- Passage Bio, Inc. (NASDAQ: PASG), a clinical-stage genetic medicines company focused on developing transformative therapies for rare, monogenic central nervous system disorders, today announced that management will participate in two upcoming virtual investor conferences in June: Jefferies Healthcare ConferenceFormat: PresentationDate: Wednesday, June 2, 2021Time: 4:30 p.m. ET Goldman Sachs 42nd Annual Global Healthcare ConferenceFormat: Fireside chatDate: Thursday, June 10, 2...

Laura Chico ... (+2)
  • Laura Chico
  • Kenneth Shields
Laura Chico ... (+2)
  • Laura Chico
  • Kenneth Shields
 PRESS RELEASE
PASG PASSAGE BIO (Health Care)

Passage Bio Reports First Quarter 2021 Financial Results and Recent Bu...

Passage Bio Reports First Quarter 2021 Financial Results and Recent Business Highlights Dosed first patient with infantile GM1 gangliosidosis in Imagine-1 Phase 1/2 trial of PBGM01, initial safety and 30-day biomarker data expected 4Q21Received multiple regulatory clearances for clinical trial initiations for three most advanced pipeline programs Expected enrollment of first patient in Phase 1/2 FTD-GRN trial in 2Q/3Q21 and first patient in Phase 1/2 Krabbe trial in 3Q21Continued to advance pipeline under leadership of newly appointed Chief R&D Officer Eliseo Salinas, M.D., MSc. Appointed M...

 PRESS RELEASE
PASG PASSAGE BIO (Health Care)

Passage Bio Announces Inducement Award for Newly Appointed Chief Comme...

Passage Bio Announces Inducement Award for Newly Appointed Chief Commercial Officer Under Nasdaq Listing Rule 5635(c)(4) PHILADELPHIA, July 21, 2021 (GLOBE NEWSWIRE) -- Passage Bio, Inc. (Nasdaq: PASG), a clinical-stage genetic medicines company focused on developing transformative therapies for rare, monogenic central nervous system (CNS) disorders, today announced it has granted an inducement award to the company’s newly appointed Chief Commercial Officer, M. Maria Törnsén, under an inducement plan adopted by its board of directors. Passage Bio granted an option to purchase 200,000 s...

 PRESS RELEASE
PASG PASSAGE BIO (Health Care)

Passage Bio to Participate in Upcoming June Investor Conferences

Passage Bio to Participate in Upcoming June Investor Conferences PHILADELPHIA, May 26, 2021 (GLOBE NEWSWIRE) -- Passage Bio, Inc. (NASDAQ: PASG), a clinical-stage genetic medicines company focused on developing transformative therapies for rare, monogenic central nervous system disorders, today announced that management will participate in two upcoming virtual investor conferences in June: Jefferies Healthcare ConferenceFormat: PresentationDate: Wednesday, June 2, 2021Time: 4:30 p.m. ET Goldman Sachs 42nd Annual Global Healthcare ConferenceFormat: Fireside chatDate: Thursday, June 10, 2...

Laura Chico ... (+2)
  • Laura Chico
  • Kenneth Shields
Laura Chico ... (+2)
  • Laura Chico
  • Kenneth Shields
 PRESS RELEASE
PASG PASSAGE BIO (Health Care)

Passage Bio Reports First Quarter 2021 Financial Results and Recent Bu...

Passage Bio Reports First Quarter 2021 Financial Results and Recent Business Highlights Dosed first patient with infantile GM1 gangliosidosis in Imagine-1 Phase 1/2 trial of PBGM01, initial safety and 30-day biomarker data expected 4Q21Received multiple regulatory clearances for clinical trial initiations for three most advanced pipeline programs Expected enrollment of first patient in Phase 1/2 FTD-GRN trial in 2Q/3Q21 and first patient in Phase 1/2 Krabbe trial in 3Q21Continued to advance pipeline under leadership of newly appointed Chief R&D Officer Eliseo Salinas, M.D., MSc. Appointed M...

 PRESS RELEASE
PASG PASSAGE BIO (Health Care)

Passage Bio Announces Inducement Award for Newly Appointed Chief Comme...

Passage Bio Announces Inducement Award for Newly Appointed Chief Commercial Officer Under Nasdaq Listing Rule 5635(c)(4) PHILADELPHIA, July 21, 2021 (GLOBE NEWSWIRE) -- Passage Bio, Inc. (Nasdaq: PASG), a clinical-stage genetic medicines company focused on developing transformative therapies for rare, monogenic central nervous system (CNS) disorders, today announced it has granted an inducement award to the company’s newly appointed Chief Commercial Officer, M. Maria Törnsén, under an inducement plan adopted by its board of directors. Passage Bio granted an option to purchase 200,000 s...

 PRESS RELEASE
PASG PASSAGE BIO (Health Care)

Passage Bio to Participate in Upcoming June Investor Conferences

Passage Bio to Participate in Upcoming June Investor Conferences PHILADELPHIA, May 26, 2021 (GLOBE NEWSWIRE) -- Passage Bio, Inc. (NASDAQ: PASG), a clinical-stage genetic medicines company focused on developing transformative therapies for rare, monogenic central nervous system disorders, today announced that management will participate in two upcoming virtual investor conferences in June: Jefferies Healthcare ConferenceFormat: PresentationDate: Wednesday, June 2, 2021Time: 4:30 p.m. ET Goldman Sachs 42nd Annual Global Healthcare ConferenceFormat: Fireside chatDate: Thursday, June 10, 2...

Laura Chico ... (+2)
  • Laura Chico
  • Kenneth Shields
Laura Chico ... (+2)
  • Laura Chico
  • Kenneth Shields
 PRESS RELEASE
PASG PASSAGE BIO (Health Care)

Passage Bio Reports First Quarter 2021 Financial Results and Recent Bu...

Passage Bio Reports First Quarter 2021 Financial Results and Recent Business Highlights Dosed first patient with infantile GM1 gangliosidosis in Imagine-1 Phase 1/2 trial of PBGM01, initial safety and 30-day biomarker data expected 4Q21Received multiple regulatory clearances for clinical trial initiations for three most advanced pipeline programs Expected enrollment of first patient in Phase 1/2 FTD-GRN trial in 2Q/3Q21 and first patient in Phase 1/2 Krabbe trial in 3Q21Continued to advance pipeline under leadership of newly appointed Chief R&D Officer Eliseo Salinas, M.D., MSc. Appointed M...

ResearchPool Subscriptions

Get the most out of your insights

Get in touch